Hepatic Encephalopathy — Acute Management

Key Points

• Hepatic encephalopathy is a clinical diagnosis and a diagnosis of exclusion in the patient with altered mental status.
• Do not diagnose or grade HE solely from an ammonia concentration.
• Search aggressively for precipitants such as infection, GI bleeding, constipation, dehydration, AKI, electrolyte disturbance, and sedatives.
• Lactulose is first-line therapy and should be titrated to about 2 to 3 soft stools daily after initial improvement.
• Excess lactulose can cause dehydration and electrolyte abnormalities that worsen encephalopathy.
• Rifaximin is an important adjunct for recurrent or inadequately controlled overt HE.
• Protein restriction is not recommended as routine treatment.
• Severe encephalopathy may require ICU care and airway protection.

Algorithm

1. Stabilize airway, breathing, circulation, and check glucose.
2. Confirm advanced liver disease or portosystemic shunt history and evaluate alternative causes of altered mental status.
3. Search for infection, bleeding, constipation, dehydration, AKI, electrolyte abnormalities, sedatives, and recent TIPS.
4. Start lactulose and titrate to clinical improvement followed by 2 to 3 soft stools daily.
5. Treat the precipitant directly and perform diagnostic paracentesis when indicated in cirrhosis with ascites.
6. Add or continue rifaximin for recurrent disease or inadequate control.
7. Avoid unnecessary sedatives and avoid routine protein restriction.
8. Admit or escalate to ICU based on airway safety, hemodynamics, precipitating illness, and encephalopathy severity.

Clinical Synopsis & Reasoning

Hepatic encephalopathy ranges from subtle cognitive impairment to disorientation, somnolence, asterixis, stupor, and coma. In emergency care, the diagnosis is clinical and should not be reduced to an ammonia result. A patient with cirrhosis and altered mental status can also have intracranial hemorrhage, infection, alcohol withdrawal, sedative toxicity, hypoglycemia, electrolyte disturbance, uremia, or hypoxia. The correct reasoning step is to recognize HE while actively excluding alternative and concurrent causes.

Common precipitants include infection, gastrointestinal bleeding, constipation, dehydration or overdiuresis, acute kidney injury, electrolyte abnormalities, sedatives, excess alcohol, missed lactulose, and progression of liver disease. Recent TIPS placement can increase risk. Examination should assess airway protection, level of consciousness, asterixis, focal neurologic deficits, signs of infection, GI bleeding, ascites, volume status, and medication effects. A focal deficit, head trauma, or atypical course should lower the threshold for neuroimaging.

Ammonia contributes to pathophysiology but the blood concentration correlates poorly with clinical grade. A high value does not prove that HE is the cause of confusion, and serial levels should not be used to titrate therapy. A normal or unexpectedly low ammonia can be a reason to reconsider the diagnosis, but it does not replace the clinical evaluation.

Grading severity helps determine disposition. Patients with mild confusion may be able to protect the airway, while grade III or IV encephalopathy can require intensive monitoring and intubation. Airway decisions should be based on actual protective reflexes, ventilation, aspiration risk, and trajectory rather than a numeric HE grade alone.

Treatment Strategy & Disposition

Treat the precipitating factor in parallel with ammonia-lowering therapy. Obtain cultures and give appropriate antibiotics when infection is suspected; control GI bleeding; correct hypovolemia, kidney injury, hypokalemia, or hyponatremia; stop unnecessary sedatives; and relieve constipation. Diagnostic paracentesis is important in hospitalized or clinically deteriorating patients with cirrhosis and ascites because spontaneous bacterial peritonitis can present primarily as encephalopathy.

Lactulose is first-line therapy for overt HE. In an acute episode it can be given orally or by nasogastric tube in repeated doses until bowel movements begin, then titrated to approximately 2 to 3 soft stools per day. Rectal administration is an option when enteral delivery is unsafe or impractical. More lactulose is not always better: excessive diarrhea causes dehydration, hypernatremia, hypokalemia, skin injury, and can itself perpetuate encephalopathy. Titrate to clinical response and stool target rather than continuous diarrhea.

Rifaximin reduces intestinal ammonia-producing bacteria and is commonly added for recurrent overt HE or inadequate control with lactulose. A typical regimen is 550 mg orally twice daily. It is particularly important for secondary prevention after recurrent episodes. It is not a substitute for correcting the precipitant.

Avoid routine protein restriction. Patients with cirrhosis are vulnerable to sarcopenia, and current hepatology guidance supports adequate protein intake rather than reducing nutrition to lower ammonia. Admit patients with a first severe episode, uncertain diagnosis, infection, GI bleeding, kidney injury, inability to take therapy, or significant altered consciousness. ICU care is appropriate for airway compromise, shock, severe agitation requiring close monitoring, or grade III to IV encephalopathy.

Epidemiology / Risk Factors

• HE is a common complication of decompensated cirrhosis and portosystemic shunting.
• Prior overt HE strongly predicts recurrent episodes.
• TIPS can precipitate or worsen HE in susceptible patients.
• Infection and GI bleeding are frequent triggers of hospitalization for HE.
• Sarcopenia is associated with worse outcomes in cirrhosis and can impair ammonia handling.

Investigations

Common Triggers

Pharmacology

Prognosis / Complications

• An episode of overt HE signals advanced liver disease and is associated with increased mortality and rehospitalization.
• Mental status often improves substantially when the precipitant is corrected and lactulose is effective.
• Recurrent HE can impair driving, work, medication adherence, and caregiver burden.
• Persistent or recurrent HE despite optimized therapy should prompt hepatology evaluation and reassessment of shunts, TIPS, and transplant candidacy.
• Failure to improve should trigger renewed search for infection, intracranial disease, drugs, metabolic disturbance, or nonconvulsive seizures.

Patient Education / Counseling

• Explain that HE often recurs when a trigger develops and that early recognition matters.
• Teach lactulose titration to a stool goal rather than a fixed number of doses.
• Warn that severe diarrhea, dizziness, or reduced intake can cause dehydration and should prompt medication adjustment and clinical contact.
• Avoid alcohol and unnecessary sedating medications.
• Caregivers should watch for sleep reversal, subtle confusion, missed medications, falls, or unsafe driving.
• Arrange hepatology follow-up after a new or recurrent episode and discuss transplant evaluation when appropriate.

Notes

The most useful ammonia test in HE is often the clinical question it forces: could something else be causing this patient's encephalopathy? A markedly elevated value can coexist with many degrees of cognition, while a patient with cirrhosis can have stroke, sepsis, withdrawal, or drug toxicity at the same time. Treat the patient rather than the laboratory number.

Lactulose should be taught as a titrated medication. The goal after acute improvement is a small number of soft bowel movements, not relentless diarrhea. Dehydration and hypokalemia from overtreatment can create another precipitant and contribute to rapid readmission.

References

1. AASLD: Back to Basics, Decoding Hepatic Encephalopathy — Link
2. AASLD Practice Guidance: Cirrhosis and Complications — Link